David Pomerantz, Chief Commercial Officer at Syapse
Syapse, a real-world evidence company accelerating the delivery of precision medicine through the Syapse Learning Health Network™, today announced the appointment of David Pomerantz as Chief Commercial Officer. In his new role as Chief Commercial Officer, Pomerantz will lead the future direction of Syapse’s commercial endeavors and expand its life sciences partnerships across the Syapse Learning Network.
Pomerantz Bio/Background
Read More
Impact of Precision Medicine| News, Policy, Analysis, Insights - HIT Consultant
FDA, Syapse Expand Research to Generate Real-World Data Related to COVID-19 and Cancer
What You Should Know:
The FDA and Syapse announce research collaboration expansion
to address urgent public health challenges including supporting FDA’s goal of
rapid understanding of COVID-19.
As part of the research, Syapse is partnering with FDA’s
Oncology Center of Excellence to investigate methods to derive RWD from
multiple sources including electronic health records, registries and molecular
data
Syapse, a real-world
evidence company accelerating the delivery of precision
Read More
M&A Analysis: 3 Benefits of Siemens Healthineers’ $16.4B Acquisition of Varian Medical
What You Should Know:
- Siemens Healthineers and Varian Medical announce a $16.4B deal in an all-cash transaction on 2nd August 2020.
- Deal expected to close in 1H 2021.
- Varian Medical will maintain its brand name and operate “independently”
- Siemens AG will drop holding in Siemens Healthineers from 85% to 72% as part of the transaction.
News of the deal between Siemens Healthineers and Varian Medical will have caught many industry onlookers off guard on Sunday evening.
Read More
HHS Taps Fenway Health as Pilot Site for Precision Medicine Project
What You Should Know:
- Fenway
Health has been selected as the pilot site to participate in the Advancing
Standards for Precision Medicine (ASPM) project.
- The ASPM project
is focused on how healthcare providers can systematically identify the
socio-economic factors that may impact the health of patients in order to
provide more individualized care that reflects patients’ needs.
Fenway Health, a
Boston, MA-based Federally Qualified Community Health Center (FQCHC)
Read More
Consumer Genetic Tests Accelerate Precision Medicine for Some Providers
Joel Diamond, MD, FAAFP, Chief Medical Officer at 2bPrecise
Direct-to-consumer (DTC) genetic tests have been on the scene for some time now. The Federal Drug Administration (FDA) approved the first DTC test on three specific BRCA1/BRCA2 breast cancer gene mutations more than two years ago. Six months after that, the agency similarly green-lighted a DTC pharmacogenomic (PGx) test to examine 33 variants for eight different genes that indicate how effectively patients metabolize specific
Read More
Syapse Lands $30M to Accelerate Real-World Evidence in Oncology
What You Should Know:
- Syapse raises $30M in new equity funding to enable healthcare providers to deliver the best care to every cancer patient through precision medicine.
- Syapse partners with health systems, life sciences companies, and regulators to deliver clinical, programmatic, and research insights from the world’s largest network of health systems focused on precision medicine.
Syapse, a San
Francisco, CA-based provider of precision oncology
solutions announced $30
Read More
AHA Launches COVID-19 Data Challenge to Address Health Disparities Among African Americans, Hispanics, Native Americans in Rural Areas
What You Need to Know:
- American Heart Association, Hitachi Vantara and BurstIQ launch COVID-19 Data Challenge to bring global COVID-19 datasets to researchers and clinicians to examine the relationship with other health conditions and health disparities.
- Each participant of the challenge will be provided a free, HIPPA compliant and FedRAMP certified, secure Precision Medicine Platform (PMP) workspace to conduct analyses.
The American Heart Association, the
Read More
The DNA Company Acquires AI Digital Therapeutics App for $30M to Form My Next Health
What You Should Know:
- DNA Company acquires AI-based digital therapeutics app My Pain Sensei (MPS) to form My Next Health and is building a COVID-19 risk assessment platform to help people understand their risks of developing serious COVID-19 complications.
- The acquisition combines functional genomics with conversational AI for patient self-management apps and disease tracking tools designed to inform clinician-patient interactions.
Leading functional genomics provider The
Read More
Machine Learning Will Transform Medicine, but Only if We Use it Right
Natalie LaFranzo, Ph.D. is VP, Market Development of Cofactor Genomics
World chess champion Garry Kasparov made headlines all over the world in 1997 for something that he probably wasn’t very excited about. He lost a chess match. To a computer.
It was an IBM supercomputer called Deep Blue and its victory in that New York City match marked the first time a reigning world chess champion had been defeated by a computer under tournament conditions. It was also a symbolically significant event,
Read More
COVID-19 Outbreak: The Opportunity & Importance of Health Informatics
Never before has health informatics played a greater role in public health than during the COVID-19 pandemic. While the Health IT industry is certainly challenged due to the overall disruption to the healthcare system, the pandemic undoubtedly underscores the opportunity and importance of health informatics, such as telehealth, remote patient monitoring, patient engagement, AI-based drug discovery, precision medicine, and clinical decision support, but nowhere more pressing than the fields of
Read More
